Formycon AG FYB
XETR · Germany · Health Technology
€19.40+0.06 (+0.31%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Formycon AG (WBO:FYB) reports a significant revenue surge and improved EBITDA, driven by commercial momentum and strategic partnerships.
MUNICH, GERMANY and BANGALORE, INDIA - July 14, 2026 (NEWMEDIAWIRE) - Formycon AG (FSE: FYB, Prime Standard, "Formycon") and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE, "OneSource"), a multi-modality specialty pharma CDMO, tod...
As European markets navigate the complexities of geopolitical developments and economic shifts, such as the ongoing U.S.-Iran negotiations and supply chain challenges, investors are increasingly focused on identifying growth opportunities within the region. In this environment, companies with high insider ownership can offer potential advantages, as they often align management's interests with those of shareholders, fostering long-term growth strategies amidst market uncertainties.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.